A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone

Trial Profile

A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 20 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 21 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Jan 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top